WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H122421
CAS#: 37988-18-4
Description: LM22A-4 is TrkB receptor agonist and is a candidate for treatment of Huntington’s disease.
Hodoodo Cat#: H122421
Name: LM22A-4
CAS#: 37988-18-4
Chemical Formula: C15H21N3O6
Exact Mass: 339.14
Molecular Weight: 339.350
Elemental Analysis: C, 53.09; H, 6.24; N, 12.38; O, 28.29
Synonym: LM22A-4; LM22A4; LM 22A4
IUPAC/Chemical Name: N1,N3,N5-tris(2-hydroxyethyl)benzene-1,3,5-tricarboxamide
InChi Key: RGWJKANXFYJKHN-UHFFFAOYSA-N
InChi Code: InChI=1S/C15H21N3O6/c19-4-1-16-13(22)10-7-11(14(23)17-2-5-20)9-12(8-10)15(24)18-3-6-21/h7-9,19-21H,1-6H2,(H,16,22)(H,17,23)(H,18,24)
SMILES Code: OCCNC(C1=CC(C(NCCO)=O)=CC(C(NCCO)=O)=C1)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 339.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Ding Y, Chow SH, Chen J, Brun APL, Wu CM, Duff AP, Wang Y, Song J, Wang JH,
Wong VHY, Zhao D, Nishimura T, Lee TH, Conn CE, Hsu HY, Bui BV, Liu GS, Shen HH.
Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an
experimental glaucoma model. Acta Biomater. 2021 May;126:433-444. doi:
10.1016/j.actbio.2021.03.043. Epub 2021 Mar 24. PMID: 33774200.
2: Fletcher JL, Dill LK, Wood RJ, Wang S, Robertson K, Murray SS, Zamani A,
Semple BD. Acute treatment with TrkB agonist LM22A-4 confers neuroprotection and
preserves myelin integrity in a mouse model of pediatric traumatic brain injury.
Exp Neurol. 2021 May;339:113652. doi: 10.1016/j.expneurol.2021.113652. Epub 2021
Feb 18. Erratum in: Exp Neurol. 2021 Sep;343:113790. PMID: 33609501.
3: Nguyen HTH, Wood RJ, Prawdiuk AR, Furness SGB, Xiao J, Murray SS, Fletcher
JL. TrkB Agonist LM22A-4 Increases Oligodendroglial Populations During Myelin
Repair in the Corpus Callosum. Front Mol Neurosci. 2019 Aug 27;12:205. doi:
10.3389/fnmol.2019.00205. PMID: 31507374; PMCID: PMC6718610.
4: Yu G, Wang W. Protective effects of LM22A-4 on injured spinal cord nerves.
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6526-32. PMID: 26261531; PMCID:
PMC4525865.
5: Kajiya M, Takeshita K, Kittaka M, Matsuda S, Ouhara K, Takeda K, Takata T,
Kitagawa M, Fujita T, Shiba H, Kurihara H. BDNF mimetic compound LM22A-4
regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade.
Int Immunopharmacol. 2014 Apr;19(2):245-52. doi: 10.1016/j.intimp.2014.01.028.
Epub 2014 Feb 11. PMID: 24530412.
6: Fletcher JL, Dill LK, Wood RJ, Wang S, Robertson K, Murray SS, Zamani A,
Semple BD. Corrigendum to "Acute treatment with TrkB agonist LM22A-4 confers
neuroprotection and preserves myelin integrity in a mouse model of pediatric
traumatic brain injury" [Experimental Neurology 339 (2021): 113652]. Exp Neurol.
2021 Sep;343:113790. doi: 10.1016/j.expneurol.2021.113790. Epub 2021 Jun 26.
Erratum for: Exp Neurol. 2021 May;339:113652. PMID: 34187696.